Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

774.84 +12.66 (+1.66%)
Streaming Delayed Price Updated: 2:49 PM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Why Hims & Hers Health Stock Just Popped
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks. 
Via Benzinga
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?
Shutting down an acquisition caught investor attention, but there's more to the story. 
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Why Eli Lilly Stock Flopped Today
Via The Motley Fool
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years
Via Benzinga
The Reality of Trump's Tariffs
Via The Motley Fool
Topics Government
The State of Weight Loss Drugs
Via The Motley Fool
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies. 
Via Benzinga
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease. 
Via MarketBeat
3 Cold Stocks That Can Bounce Back This Week
These three stocks tumbled by at least 20% last week, but they may not be down for long. 
Via The Motley Fool
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk's experimental obesity drug failed to top Eli Lilly's Zepbound. But there's something else that rattled investors. 
Via Investor's Business Daily
3 Magnificent Growth Stocks to Buy in March
Via The Motley Fool
MarketBeat Week in Review – 03/03 - 03/07
Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue 
Via MarketBeat
Topics Economy
Discover which S&P500 stocks are making waves on Friday.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday. 
Via Chartmill
Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients
Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years. 
Via Benzinga
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
Teladoc Health is integrating LillyDirect into its Chronic Care Weight Management program, potentially boosting enrollments. 
Via Benzinga
Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
A global study shows obesity rates predicted to climb. Are weight loss drugs not doing enough or not available in enough countries? 
Via Benzinga
3 Super Growth Stocks: 2 To Buy – 1 To Sell
PLTR, LLY and NVDA are probably three of the hottest, most popular stocks on the planet today. 
Via Talk Markets
Topics Stocks / Equities
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025,... 
Via Benzinga
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support. 
Via Benzinga
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly? 
Via MarketBeat
Topics Bonds Economy Government
3 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Stock Market Sell-Off: The 9 Best Stocks to Buy Now in March (2025)
Via The Motley Fool
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
Via Benzinga
Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery
Novo Nordisk launches NovoCare Pharmacy, offering uninsured and cash-paying patients Wegovy for $499 per month. The service includes home delivery, live support, and safeguards against compounded... 
Via Benzinga
2 Mega-Cap Stocks with Exciting Potential and 1 to Turn Down
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Biotech Rally Coming In Weeks Ahead?
Large cap biopharma and MedTech stocks are leading the healthcare sector higher. 
Via Talk Markets
Topics ETFs Stocks / Equities
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.